Notch Therapeutics

Notch Therapeutics is an early-stage biotechnology company based in Vancouver, Canada, focused on immune cell therapy.

The company specializes in developing allogeneic T cell therapies using a proprietary technology platform based on induced pluripotent stem cells (iPSCs). This innovative approach allows for the large-scale production of genetically tailored T cells, making therapies more accessible and cost-effective for patients with high unmet medical needs, particularly in cancer treatment. Notch's capabilities include a synthetic engineered thymic niche platform for T cell expansion, large-scale manufacturing processes, and a computational workflow for predicting CAR-T pharmacology. The company is advancing a pipeline of allogeneic T cell therapies, including the UNi-T Cell product designed for various hematologic cancers and autoimmune conditions. Notch has secured over $100 million in funding from notable investors and has established strategic partnerships, including a collaboration with Allogene Therapeutics to develop CAR-T therapies. With a strong leadership team and a commitment to innovation, Notch Therapeutics aims to transform the landscape of cell therapies.